Cycloproscaline
Pharmaceutical compound
From Wikipedia, the free encyclopedia
Cycloproscaline (CP), also known as 4-cyclopropoxy-3,5-dimethoxyphenethylamine (4-cPrO-3,5-DMPEA), is a psychedelic drug of the phenethylamine and scaline families related to mescaline.[1][2] It is the homologue of mescaline in which the 4-methoxy group has been replaced with a 4-cyclopropoxy group.[1][2] The drug has a dose of 60 mg or more orally and a duration of 6 hours or more, but has not been fully evaluated.[1][2] It is a low-potency full agonist of the serotonin 5-HT2A receptor and also interacts with other serotonin receptors such as the serotonin 5-HT1A and 5-HT2C receptors.[2] The drug's chemical synthesis has been described.[1] Cycloproscaline was first described in the scientific literature by Daniel Trachsel and colleagues in 2013.[1] Its pharmacology was studied in greater detail in 2021.[2] The drug is not a controlled substance in Canada as of 2025.[3]
- None
| |
| Clinical data | |
|---|---|
| Other names | CP; 4-Cyclopropoxy-3,5-dimethoxyphenethylamine; 4-cPrO-3,5-DMPEA |
| Routes of administration | Oral[1][2] |
| Drug class | Serotonin receptor modulator; Serotonin 5-HT2A receptor agonist; Serotonergic psychedelic; Hallucinogen |
| ATC code |
|
| Pharmacokinetic data | |
| Duration of action | ≥6 hours[1][2] |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| Chemical and physical data | |
| Formula | C13H19NO3 |
| Molar mass | 237.299 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
